TPST

Tempest Therapeutics Inc

Add to Watchlist

Advanced Chart

10.025

+0.675(7.219%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.0973

Open

9.350

VWAP

9.85

Vol

44.03K

Mkt Cap

44.51M

Low

9.350

Amount

433.63K

EV/EBITDA(TTM)

Total Shares

22.22M

27.24M

EV/OCF(TTM)

P/S(TTM)

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-3.270

-38.65%

-3.520

-12.66%

-3.640

+15.19%

Estimates Revision

The market is revising No Change the revenue expectations for Tempest Therapeutics, Inc. (TPST) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 60.91%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+60.91%

In Past 3 Month

2 Analyst Rating

-10.22% Downside

Wall Street analysts forecast TPST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TPST is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

-10.22% Downside

Current: 10.025

Low

9.00

Averages

9.00

High

9.00

-10.22% Downside

Current: 10.025

Low

9.00

Averages

9.00

High

9.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Hold

Downgrades

$16

2025-04-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-04-10

Downgrades

Strong Buy

Hold

Reason

Tempest Therapeutics announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage programs. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisition, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company has retained MTS Health Partners, a financial advisor with experience in the biotechnology industry, to support it with the strategic evaluation process. "Notwithstanding the positive randomized data set from the amezalpat Phase 2 and its blockbuster potential in first-line HCC, as well as the potential of TPST-1495 as it moves towards a Phase 2 in FAP, the capital markets have been unavailable to support the next stage of advancement," said Stephen Brady, president and chief executive officer of Tempest. "We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what we believe are potentially life-saving therapies for patients in need. Given the positive data and commercial potential with this pipeline, as well as the clearance from FDA on the lead program's pivotal study, we believe this is a rare opportunity for a partner."

Scotiabank

George Farmer

Buy

Hold

Downgrades

$91 → $9

2025-04-10

Reason

Scotiabank

George Farmer

Price Target

$91 → $9

2025-04-10

Downgrades

Buy

Hold

Reason

Scotiabank downgraded Tempest Therapeutics to Sector Perform from Outperform.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$47 → $16

2025-03-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$47 → $16

2025-03-28

Maintains

Strong Buy

Reason

Scotiabank

George Farmer

Buy

Maintains

$13 → $7

2025-03-28

Reason

Scotiabank

George Farmer

Price Target

$13 → $7

2025-03-28

Maintains

Buy

Reason

Scotiabank analyst George Farmer lowered the firm's price target on Tempest Therapeutics to $7 from $13 and keeps an Outperform rating on the shares. No significant updates have been reported since the company received an FDA green-light to evaluate PPARa antagonist, the analyst tells investors. Given the company's constrained financial resources, further progress on this clinical program appears to be on hold, the firm adds. The company's rating on the stock reflects the "extremely attractive risk/reward opportunity" once the trial begins, the firm concludes.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$47

2024-11-13

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$47

2024-11-13

Reiterates

Strong Buy

Reason

Tempest Therapeutics announced that the company received a "Study May Proceed" letter from the U.S. Food and Drug Administration, FDA, to evaluate amezalpat, TPST-1120, in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in a pivotal randomized Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, HCC. "The clinical and regulatory team at Tempest are thrilled to receive this notice from FDA with respect to the planned pivotal Phase 3 trial to evaluate amezalpat as a potential treatment for first-line liver cancer," said Sam Whiting M.D., Ph.D., chief medical officer and head of R&D of Tempest. "Previously reported positive Phase 2 data underscore amezalpat's potential to improve the survival of patients facing this life-threatening disease, and our team is dedicated to advancing the program and bringing amezalpat to patients."

Piper Sandler

Edward Tenthoff

Buy

Maintains

$8 → $5

2024-11-13

Reason

Piper Sandler

Edward Tenthoff

Price Target

$8 → $5

2024-11-13

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tempest Therapeutics Inc (TPST.O) is -0.65, compared to its 5-year average forward P/E of -1.30. For a more detailed relative valuation and DCF analysis to assess Tempest Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.30

Current PE

-0.65

Overvalued PE

-0.34

Undervalued PE

-2.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.70

Current EV/EBITDA

-0.65

Overvalued EV/EBITDA

0.57

Undervalued EV/EBITDA

-1.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00